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Analyses from the Danish HIV Cohort Study showed 
that, despite comparable economic means and general 
education of healthcare personnel, antiretroviral treatment 
of HIV in Greenland began later and has been implemented 
at a slower pace with lower therapeutic effectiveness than 
in Denmark. However, implementation and quality of care 
improved considerably in recent years.
L
ike in Western Europe, the ﬁ  rst case of HIV was ob-
served in Greenland in the mid-1980s (1), but the 
epidemic in this isolated polar country has evolved differ-
ently compared with other industrialized countries (2). In a 
previous study we showed that most patients were infected 
through heterosexual contact and were middle-aged at the 
time of diagnosis. Many patients belonged to a socially 
marginalized group characterized by low income, unem-
ployment, and heavy drinking. Even though highly active 
antiretroviral therapy (HAART) is tax-supported and free, 
we found an overall mortality rate of 11% per year for pa-
tients given HAART during 1997–2003 (2). In a molecular 
epidemiologic study, we showed that HIV was introduced 
at least 9 times into Greenland, and that one of these in-
troductions has given rise to a circulating epidemic that 
has included 76% of all infected persons (3). Recently, we 
found 28% prevalence of transmitted drug resistance, cor-
responding well with the impression of low drug adherence 
and high risk behavior (T.V. Madsen et al., unpub. data). 
Contributing to the disappointing results could be the vast 
geography with often long distances to healthcare facilities, 
the short supply of specialized physicians, and the compo-
sition of the HIV-infected population. In 2002 the overall 
responsibility for treating HIV patients was transferred to 
the Department of Internal Medicine at Dronning Ingrids 
Hospital, Greenland’s main hospital, located in the capi-
tal, Nuuk. The chief physician at that department takes care 
of HIV patients in Nuuk and supervises treatment of HIV 
patients in other areas. With access to data from all HIV-
infected persons in Greenland and Denmark, we aimed to 
compare the Implementation and effectiveness of HAART 
during 1997–2007 in 3 areas: Nuuk; Greenland’s remote 
districts (all towns and settlements except Nuuk); and the 
Western European country of Denmark, the former colo-
nial power with which Greenland still has tight economical, 
social, and constitutional bonds.
The Study
The population-based Danish HIV Cohort Study 
(DHCS) collects clinical and paraclinical data on all HIV-
infected persons under care in Denmark and Greenland 
since 1995 (2,4), including antiretroviral treatment, HIV 
RNA (viral load), and date of death or emigration. Patients 
from DHCS were followed from ﬁ  rst visit to an HIV clinic 
until date of death, emigration, or last visit to the clinic. To 
estimate viral loads and CD4 cell counts between measure-
ments, we carried forward the last observed value. HAART 
was deﬁ  ned as combination antiretroviral treatment with at 
least 3 drugs, including at least 1 protease inhibitor (PI), or 
1 non-nucleoside reverse transcriptase inhibitor (NNRTI), 
or abacavir. On January 1 for each year of the study we es-
timated the proportion of patients receiving HAART, each 
antiretroviral drug class, and selected antiretroviral drugs. 
National guidelines in both countries have recommended 
HAART initiation at a CD4 cell count <300 cells/μL, a 
threshold that has not changed since 1997. Among patients 
who had never received HAART, we estimated the pro-
portion with a CD4 cell count <300 cells/μL, and among 
patients who had begun a HAART regimen at least 90 days 
previously, we estimated the proportion with a viral load 
<400 copies/mL. Annual mortality rates (MR) in the HIV 
population were estimated by person-years analysis; Pois-
son regression was used to test for trends over time.
Conclusions
Among 124 HIV patients in Greenland, 98 (79%) 
were infected through heterosexual contact, 78 (63%) were 
male, 111 (90%) were Inuit, and 98 (79%) were infected in 
Greenland. The median age at diagnosis was 50 years (in-
terquartile range [IQR] 40–57 years), and the median CD4 
cell count at diagnosis was 350 cells/μL (IQR 220–530 
cells/μL). Among 4,702 HIV patients in Denmark, 2,114 
(45%) were infected through homosexual contact, 1,745 
(37%) through heterosexual contact, and 537 (11%) through 
intravenous drug use; 3,542 (75%) were male; 3,723 (79%) 
were Caucasian, and 650 (14%) black African. Half, 2,370, 
56  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 1, January 2008
*Århus University Hospital, Århus, Denmark; †Copenhagen Univer-
sity Hospital Rigshospitalet, Copenhagen, Denmark; and ‡Dron-
ning Ingrids Hospital, Nuuk, Greenland
1The Danish HIV Cohort Study: Departments of Infectious Diseases 
at Copenhagen University Hospitals Rigshospitalet (J. Gerstoft, N. 
Obel) and Hvidovre (G. Kronborg), Odense University Hospital (C. 
Pedersen), Aarhus University Hospitals, Skejby (C.S. Larsen) and 
Aalborg (G. Pedersen), Herning Hospital (A.L. Laursen), Helsingør 
Hospital (B. Kvinesdal), and Kolding Hospital (A. Møller).Antiretroviral Therapy in Greenland
were infected in Denmark, 725 (15%) in Africa, and 1,046 
(22%) unknown; the median age at diagnosis was 34 years 
(IQR 28–42). The median CD4 cell count at diagnosis was 
284 cells/μL (IQR 108–490 cells/μL).
In Greenland only 3% had begun HAART on January 
1, 1997, as opposed to 28% in Denmark (Figure 1). The 
proportion on HAART increased gradually up to 81% in 
2006, but not until 2003 did the proportion in Greenland 
reach the level in Denmark. Further, as late as 2001, 96% 
of all treatment regimens in Greenland included an un-
boosted PI (26% in Denmark), and in 2002 only 7% were 
NNRTI based (40% in Denmark). At that time the Interna-
tional AIDS Society USA guidelines carefully encouraged 
the use of boosted PIs, and NNRTI-based regimens were 
considered an equally effective alternative to PI-based regi-
mens (5). Only after 2002 did the pattern shift, and in 2006 
it was similar to that in Denmark, with approximately half 
of the combinations being NNRTI based, the other half PI 
based, with ritonavir-boosted lopinavir used in 65% of all 
PI regimens on January 1. The newer PI atazanavir was 
used in only 9% of PI regimens in 2006 (28% in Denmark). 
NNRTI used in Greenland has almost exclusively been 
efavirenz, whereas in Denmark 24% of NNRTI use on 
January 1, 2006, was nevirapine. The difference between 
the curves “ever on HAART” and “currently on HAART” 
in Figure 1 reﬂ  ects the number of persons currently inter-
rupting their treatment; the proportion with interruption is 
higher in Greenland than in Denmark. Structured treatment 
interruptions have not been recommended in Greenland or 
Denmark, so these persons supposedly have interrupted 
their therapy because of compliance problems. There was 
no difference in the uptake of HAART between Nuuk and 
the remote districts in Greenland (data not shown).
Until 2002, >30% of patients not yet receiving 
HAART in Greenland had a CD4 cell count <300 cells/μL 
(Figure 2). In comparison, the proportion in Denmark has 
been <30% since 1998, with <5% having a CD4 cell count 
<200 cells/μL since 2001. Among patients ever starting 
a HAART regimen, the proportion with suppressed viral 
load in Greenland was <45% until 2003 but has increased 
to 73% in 2006 (Figure 2). Nuuk reached the 75% mark in 
2004, whereas the increase in the remote districts started 
later and reached 69% in 2006. The proportions in Den-
mark were 62% in 1998, 81% in 2003, and 88% in 2006.
The overall mortality rate among HIV patients in 
Greenland decreased from 139 (95% conﬁ  dence interval 
[CI] 81–239) per 1,000 person-years in 1995–1997 to 59 
(95% CI 35–99) in 2004–2006, corresponding to a 9% de-
crease per year (mortality rate ratio [MRR] = 0.91, 95% 
CI 0.84–0.98, p = 0.014) (Table). The decrease was most 
marked in patients in Nuuk (MRR = 0.86, 95% CI 0.77–
0.96, p = 0.006) and less in the districts (MRR = 0.96, 95% 
CI 0.86–1.08, p = 0.533).
Treatment of HIV patients in Greenland began at a 
later stage of disease and has been implemented at a slower 
pace with lower therapeutic effectiveness than in Denmark, 
despite comparable economic means, general education of 
healthcare personnel, and common therapeutic guidelines. 
From other studies we know that patient support and edu-
cation improve adherence (6) and that guideline-recom-
mended therapy is more likely to be chosen if the physician 
is specialized in HIV and has >20 HIV patients in care (7), 
regardless of whether this physician is a generalist or in-
fectious disease specialist. We observed marked improve-
ments in the choice of antiretroviral drug combinations 
and effectiveness of HAART from 2003 onwards. These 
advances coincided with the establishment of a dedicated 
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Figure 1. Proportion of patients receiving treatment on January 1, 
1996–2006 in A) Denmark and B) Greenland. Numerator, patients 
who were receiving antiretroviral therapy as part of a HAART (highly 
active antiretroviral therapy) regimen. Denominator, all patients 
under observation. NNRTI, non-nucleoside reverse transcriptase 
inhibitor; PI, protease inhibitor.team in Nuuk and were most pronounced in that city when 
compared with the remote districts. Even though this tem-
poral association does not prove causation, the improve-
ments are likely to be partly attributable to the increased 
focus on HIV in the capital. The MR among HIV patients 
in Nuuk in recent years was higher than that in Denmark, 
but part of this difference may be attributable to a high 
background mortality rate among HIV-uninfected persons 
in Greenland (2,8) and an older HIV-infected population. 
As previously reported, sexually active persons in Green-
land undergo frequent HIV testing (2), and CD4 cell counts 
were high at diagnosis, ruling out late testing as a contribu-
tor to the high MR. In conclusion, healthcare systems in 
the sparsely populated and isolated polar areas may be less 
ﬁ  t to take on state-of-the-art care and treatment for HIV or 
other diseases previously unknown in the area, and an extra 
effort from the such providers may be needed to maximize 
control of the disease.
This study was supported by unrestricted grants from the 
Greenland Health Science Foundation, the Greenland AIDS 
Foundation, and the Danish AIDS Foundation. N. Obel has re-
ceived research funding from Roche, Bristol-Myers Squibb, 
Merck Sharp & Dohme, GlaxoSmithKline, Abbott, Boehringer 
Ingelheim, Janssen-Cilag, and Swedish Orphan.
Dr Lohse is a senior researcher at the Department of Clinical 
Epidemiology, Århus University Hospital, and the Danish HIV 
Cohort Study, Copenhagen University Hospital, Rigshospitalet, 
Denmark. His primary research interests include the clinical epi-
demiology of HIV.
References
  1.   Misfeldt J, Melbye M, Hansen JP. An international meeting on pre-
venting AIDS in the polar regions. Ilulissat/Jakobshavn 26–28 Sep-
tember 1989 [in Danish]. Ugeskr Laeger. 1989;151:3496.
  2.   Lohse N, Ladefoged K, Pedersen L, Jensen-Fangel S, Sorensen HT, 
Obel N. Low effectiveness of highly active antiretroviral therapy 
and high mortality in the Greenland HIV-infected population. Scand 
J Infect Dis. 2004;36:738–42.
  3.   Madsen TV, Leitner T, Lohse N, Obel N, Ladefoged K, Gerstoft J, et 
al. Introduction of HIV type 1 into an isolated population: molecular 
epidemiologic study from Greenland. AIDS Res Hum Retroviruses. 
2007;23:675–81.
  4.   Lohse N, Hansen AB, Jensen-Fangel S, Kronborg G, Kvinesdal B, 
Pedersen C, et al. Demographics of HIV-1 infection in Denmark: 
results from The Danish HIV Cohort Study. Scand J Infect Dis. 
2005;37:338–43.
58  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 1, January 2008
INTERNATIONAL POLAR YEAR  DISPATCHES
Figure 2. A). Proportion of patients with low CD4 cell count on 
January 1, 1996–2006. Numerator, patients with a CD4 cell count 
<300 cells/μL. Denominator, all patients who had not yet been 
prescribed a highly active antiretroviral therapy (HAART) regimen. 
B) Proportion of patients with suppressed viral load on January 1, 
1996–2006. Numerator, patients with an HIV RNA <400 copies 
per mL. Denominator, all patients who had ever started a HAART 
regimen.
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